Flunarizine

Basic Flunarizine Information

• INN (International Nonproprietary Name): Flunarizine (Flunarizine hydrochloride).
• Brand Names Available In United Kingdom: Sibelium® (withdrawn; rarely available via import).
• ATC Code: N07CA03.
• Forms And Dosages: Tablet 5 mg and 10 mg; capsules 5 mg and 10 mg (capsules less common).
• Manufacturers In United Kingdom: not specified.
• Registration Status In United Kingdom: Withdrawn (rarely available via import or unlicensed supply).
• OTC / Rx Classification: Prescription-only (Rx) in markets where approved; not licensed routinely in the UK and supplied via private/unlicensed routes when used.

Critical Warnings, Restrictions And Patient Protection (UK Focus)

Who Should Be Cautious When Considering Flunarizine?

Absolute contraindications include a history of depressive illness, active depression, Parkinson’s disease or other extrapyramidal disorders, known hypersensitivity and severe hepatic insufficiency.

Elderly patients have an increased risk of parkinsonism and movement disorders when taking flunarizine.

Pregnancy use is discouraged unless advised by a specialist and breastfeeding decisions require a risk–benefit discussion with prescriber.

Patients with epilepsy or significant liver disease should avoid flunarizine or use it only under neurologist oversight.

Prescribers should follow a simple checklist before starting flunarizine.

• Checklist For Prescriber Assessment:
• Confirm full medical history including depression and movement disorders.
• Perform a mood screen (ask about current or past depressive symptoms).
• Review hepatic function and consider baseline liver history.
• Complete a full medicines review for interacting CNS depressants or dopamine antagonists.
• Document informed consent if using unlicensed or imported supply.

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Elderly people should start at 5 mg/day and be closely monitored for tremor, rigidity or akathisia.

Pregnancy use is generally discouraged unless a specialist advises that benefits outweigh risks.

Breastfeeding requires individual discussion about possible infant exposure and maternal benefits.

Patients with chronic hepatic disease should have dose reductions and extended monitoring because flunarizine is primarily hepatically metabolised.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Flunarizine commonly causes drowsiness and impaired alertness which can affect driving and safety‑critical work.

Patients must be warned not to drive or operate heavy machinery until they know how flunarizine affects them.

Employers and occupational health should be informed where safety‑critical tasks are involved.

• Patient Counselling Points:
• Do not drive until you know how the medicine affects you.
• Avoid operating heavy machinery while sedated.
• Limit alcohol and other sedatives while starting treatment.
• Document counselling in clinical records and advise reporting of adverse effects.

• Prescriber/Pharmacy Checklist:
• Record driving and occupational advice given.
• Arrange follow‑up to assess sedation and motor symptoms.
• Advise Yellow Card reporting for suspected adverse reactions.

Q&A — “Can I Drive After Taking It In The UK?”

No—do not drive or operate heavy machinery until you know how flunarizine affects you.

If you experience drowsiness or slowed reactions you must refrain from driving.

Report any suspected side effects via the MHRA Yellow Card scheme.

Usage Basics: Names, Classification And Status In The UK

INN, Brand Names Available In The UK

INN

Flunarizine (Flunarizine hydrochloride).

Brand Example

Sibelium® (widely used across Europe; withdrawn in the UK but available in other countries such as Romania, Spain, France, Italy and Poland).

Manufacturers

Gedeon Richter and various generics (Teva, Zentiva, Medochemie); traded via international suppliers for unlicensed import.

Legal Classification And UK Context

Flunarizine is prescription‑only (POM/Rx) in all markets where it is licensed.

In the United Kingdom the product is not licensed routinely and is often supplied only via private prescribing or unlicensed import pathways that must follow MHRA guidance.

NHS prescribing is uncommon and clinicians should document reasons and obtain consent when using unlicensed supplies.

• Practical Notes For Prescribers:
• Use a private prescription or an unlicensed import route when necessary.
• Document clinical justification and informed consent in the record.
• Be aware of NHS prescription charging rules: England usually applies charges, while Scotland, Wales and Northern Ireland have different arrangements.

Dosing Guide (Practical UK Regimens And Adjustments)

Standard Regimens (NHS‑Style Guidance)

The typical adult dose used internationally is 10 mg once daily at night for migraine prophylaxis or vertigo.

If intolerance occurs, reduce to 5 mg once daily and reassess.

Treatment should be assessed after a minimum of 2–3 months to judge efficacy and reviewed by six months; stop if ineffective.

Planned drug holidays, for example two months on then one month off, may reduce the long‑term risk of movement disorders.

• Titration Checklist:
• Start at the lowest effective dose where possible.
• Review response at 6–12 weeks and at six months.
• Record weight, mood and motor symptoms during follow‑up.

Adjustments For Comorbidities

In hepatic impairment consider halving the dose and increasing monitoring because flunarizine is mainly hepatically metabolised.

Children are generally not recommended to receive flunarizine due to limited data.

A history of epilepsy increases seizure risk and requires specialist oversight if flunarizine is considered.

• Comorbidity Checklist:
• Check liver history and consider liver function tests where clinically indicated.
• Document specialist advice for epilepsy or severe comorbidity.
• Monitor mood and movement signs frequently in high‑risk patients.

Q&A — “What If I Miss A Dose?”

If you miss a dose, take it as soon as you remember unless it is almost time for the next dose—do not double up.

If in doubt, contact your pharmacist or prescriber for advice.

Interaction Chart: Medicines, Food And Lifestyle

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Alcohol and other central nervous system depressants potentiate sedation and should be minimised when starting flunarizine.

Caffeine does not reliably reverse drug‑induced drowsiness and should not be relied on for safety‑critical tasks.

There are no critical specific food interactions, but patients should be counselled about potential weight gain and advised on diet and exercise monitoring.

Common Drug Conflicts (MHRA Yellow Card Data And Known Interactions)

Flunarizine increases extrapyramidal risk when combined with antipsychotics or other dopamine antagonists.

Concurrent benzodiazepines, opioids or other sedatives will increase drowsiness and impairment of alertness.

Flunarizine can lower the seizure threshold and should be used cautiously with drugs like bupropion or tramadol.

• Encourage patients and clinicians to report suspected interactions via Yellow Card.

User Reports, Patient Trends And Lived Experience (UK Sources)

What Patients Say When They Use Flunarizine In The UK Context.

Summaries across UK patient sites show mixed experience: some people report meaningful reductions in migraine or vertigo frequency, while many note troublesome side effects.

• Sentiment Categories:
• Efficacy: some report fewer migraine days or reduced vertigo intensity after weeks.
• Tolerability: common complaints are drowsiness, weight gain and mood changes.
• Access: many UK users report difficulty obtaining flunarizine because the product is withdrawn domestically, prompting private prescriptions or imported supplies.

Clinicians should validate anecdotal reports against formal safety data and document informed consent when using unlicensed or imported supplies.

Access And Purchase Options In The UK

Major Community Pharmacy Routes

High‑street chains will only supply licensed products on a valid prescription.

Because Sibelium® is withdrawn in the UK, routine NHS supply is very unlikely.

Pharmacies may dispense unlicensed imports only on an appropriate private prescription with correct import paperwork and verification.

• Pharmacist Verification Checklist:
• Confirm valid private prescription and import documentation.
• Check manufacturer and batch details on imported packs.
• Provide counselling and a patient information leaflet even for unlicensed supplies.

Online Pharmacies, E‑Prescriptions And Unlicensed Imports

Patients increasingly obtain flunarizine via EU online pharmacies supplying imported product against a private prescription.

Before purchase, confirm pharmacy registration and that patient counselling is available.

• Pre‑Purchase Checklist:
• Valid prescription present.
• MHRA import compliance where applicable.
• Supplier is a registered pharmacy and provides batch/expiry verification.
• Patient counselling offered and documented.

In our online pharmacy, flunarizine is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Mechanism Of Action And Pharmacology (Lay + Clinical)

Simplified Explanation

Calcium Channel Blocker

Flunarizine acts as a selective calcium‑entry blocker that stabilises neuronal excitability.

Antihistamine

It has antihistaminic and sedative properties that contribute to drowsiness.

Extrapyramidal

CNS penetration explains the risk of movement disorders such as parkinsonism and tremor.

Onset of benefit is gradual and may take several weeks to become apparent for migraine prevention.

Clinical Pharmacology And Metabolism

Flunarizine is hepatically metabolised and has a long half‑life permitting once‑daily dosing.

CNS penetration accounts for sedative and movement‑related adverse effects.

There is no specific antidote for overdose; management is supportive.

Indications And Off‑Label Uses In UK Practice

MHRA‑Approved Uses (Internationally) And UK Position

• International licences commonly list migraine prophylaxis and vertigo (central and peripheral) as indications.
• In the UK the product is withdrawn and formal routine licensing is absent.
• When used in the UK it is typically supplied privately or as an unlicensed import for refractory cases.

Off‑Label Practices In NHS And Private Care

• Off‑Label Or Specialist Uses:
• Vestibular migraine and refractory chronic migraine where first‑line agents have failed.
• Occasional adjunctive use in epilepsy under specialist guidance (rare).
• Emphasise documentation, specialist review and close monitoring for depression and parkinsonism.

• Clinician Justification And Follow‑Up Checklist:
• Record previous treatments tried and reasons for failure or contraindication.
• Obtain informed consent for unlicensed supply and document discussion.
• Arrange specialist review where appropriate and a monitoring schedule for mood and motor signs.

Key Clinical Findings (Recent UK/EU Evidence 2022–2025)

What Does Recent Evidence Say About Flunarizine?

European trials show consistent efficacy signals for episodic and vestibular migraine reduction versus placebo, though trial sizes and designs vary.

Safety signals—sedation, weight gain, depressive symptoms and parkinsonism with long use—limit broad adoption.

Many positive studies pre‑date 2020 and high‑quality head‑to‑head UK RCT evidence from 2022–2025 is sparse.

• Clinician Advice:
• Balance efficacy signals against established safety risks before prescribing.
• Report outcomes to local registries or audits where possible.

Alternatives Matrix For NHS Prescribers

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Pros For Alternatives: stronger evidence base in NHS practice for many agents, clearer licensing status and monitoring pathways.
• Cons For Alternatives: side effects and contraindications vary and some are unsuitable in pregnancy or for comorbidities.
• Prescribing Checklist Before Considering Flunarizine:
• Document trials of first‑line options and reasons for failure.
• Record specialist opinion and informed consent for unlicensed supply.

Common Patient Questions (UK Consultations)

Short Answers To The Questions Patients Ask Most Often.

• Will It Make Me Sleepy? — Yes. Drowsiness is common; avoid driving until you know the effect.
• How Quickly Will It Work? — Expect 6–12 weeks to judge benefit for migraine prevention.
• Will It Cause Weight Gain? — Weight gain is commonly reported; advise diet and exercise monitoring.
• Can I Stop Suddenly? — Gradual discontinuation is preferred after long‑term use; discuss with prescriber.

Signpost patients to the MHRA Yellow Card scheme for side‑effect reporting and the NHS website for further advice.

NHS Cost & Access Comparison (Recommended Table)

Two Tables To Help Patients Compare Sources And Regional Rules.

• Patient Checklist For Requesting A Private Prescription:
• Check entitlement and exemptions for prescription charges in your region.
• Ask prescriber to document clinical rationale for unlicensed supply.
• Obtain written information on import status, cost and expected delivery time.

Registration, Regulation And Reporting (MHRA & NHS Frameworks)

MHRA Approval Process And UK Licensing Status

Flunarizine is not routinely licensed in the United Kingdom and Sibelium® is listed as withdrawn.

Prescribers using imported or unlicensed supplies must follow MHRA guidance on unlicensed medicines, documenting clinical need and obtaining informed consent.

Check and retain import documentation and batch/manufacturer details when supplying unlicensed product.

Prescribing Framework And Patient Safety Reporting

Report suspected adverse reactions to the MHRA Yellow Card scheme.

Private prescribers should ensure appropriate follow‑up and coordinate care with the patient’s NHS GP where appropriate.

• Prescriber Safety Checklist:
• Obtain informed consent and document the unlicensed status.
• Baseline assessments: mood screen, motor exam, weight and liver history.
• Set a monitoring schedule and record follow‑up appointments.

Storage, Handling And Travel Guidance For UK Households

Household Storage (Cold/Damp Climate Considerations)

Store flunarizine below 25°C in its original packaging and protect from moisture and light.

In UK homes prone to damp, keep tablets in a dry cabinet away from bathrooms and heaters.

For travel avoid exposure to extremes of temperature and do not freeze; check expiry dates on imported supplies carefully.

• Storage Checklist For Patients:
• Keep tablets in original blister or bottle.
• Store in a dry, cool place away from direct sunlight.
• Check batch and expiry dates on imported packs.

Pharmacy Handling, Labelling And Disposal

Pharmacies supplying imported or unlicensed packs must ensure clear labelling and provide a patient information leaflet.

Advise patients to return unused medicines to a pharmacy for safe disposal—do not flush medicines down the sink or toilet.

Guidelines For Proper Use, Monitoring And Pharmacist Counselling

UK Pharmacist Counselling Style (Brief Script)

Concise Counselling Script For Pharmacy Staff:

Explain the indication and that benefit can take several weeks.

Confirm dose and missed‑dose advice (do not double up if a dose is missed).

Highlight main side effects: drowsiness, weight gain, mood change and movement symptoms.

Advise on driving/work safety and when to seek urgent help for suicidal thoughts or new motor symptoms.

Encourage reporting of side effects via Yellow Card and document patient understanding.

• Standardised Counselling Checklist:
• Indication and expected onset.
• Dosing, missed dose and stopping advice.
• Main adverse effects and safety actions.
• Driving and occupational safety guidance.

NHS Patient Safety Advice And Monitoring Schedule

Recommend baseline mood assessment, motor examination and weight recording prior to starting treatment.

Follow‑up at 4–6 weeks to assess tolerability and again at 3 months to review efficacy.

If treatment continues, consider reviews every six months with attention to mood and movement symptoms.

Discontinue promptly if signs of depression or parkinsonism develop.

For unlicensed supplies ensure documented informed consent and provide a shared‑care letter to the patient’s GP.

Delivery Across United Kingdom